Shedding light on some peer-reviewed randomized control trials conducted so far with this anti viral drug touted for use in alleviating intensive care in severe COVID-19 patients.

On May 22, 2020 the New England Journal of Medicine published a preliminary report of a double-blind randomized, placebo-controlled trial of intravenous remdesivir.

They concluded that remdesivir is superior to placebo in shortening recovery time in adults hospitalized with COVID-19. A total of 1063 patients underwent randomization.

On April 29, 2020 the Lancet published a double-blind randomized, placebo-controlled multicentre trial of intravenous remdesivir.

237 patients were studied, in which no statistically significant clinical benefit was ascertained, however a numerical reduction in time to clinical improvement was observed in hospitialized COVID-19 patients.

A five day course of #remdesivir could cost Rs 35000-42000, as US based @GileadSciences says Indian licensees are free to price the drug which will be available next month. Will @nppa_india invoke para 19? Reporting with @rdivia pic.twitter.com/dbgdYz8kru

— Teena Thacker (@Teensthack) June 4, 2020

Medical coronavirus covid19 gilead remdesivir